Translational Modeling of Antibacterial Agents

The golden era of antibiotic discovery almost 60 years ago seems to be an interlude in the eternal battle against bacteria; the spread of resistant bacteria has led to the emergence of highly resistant pathogens and hard-to-treat infections. In vitro infection models have made it possible to gather time-course data regarding antibiotic and bacteria interaction. The main drawback of these in vitro systems is that they do not take into account the host immune system, drug-protein binding, and characteristics of the infection site. Hence, animal studies are important to gain insights into the host response and the progression of infection. Modeling antimicrobials has the distinct advantage wherein the target is readily accessible since the bacterial load can be quantified in both in vitro and in vivo experimental conditions. The increasing knowledge base about molecular mechanisms of interactions between antibiotics and antibiotic targets, coupled with advanced experimental techniques and computational capability, makes the development of mechanism-based PK/PD models incorporating receptor binding and bacterial physiology possible. This new generation of mechanism-based PK/PD models will enable the exploration and increased understanding of the underlying complex mechanisms of the infectious process. The transition toward systems-based approaches requires the ability to integrate diverse data types and experimental platforms. Most approaches for translating preclinical antimicrobial research focus only on antibiotic activity and interactions between the drug and bacteria. Mathematical modeling can assist in this process by integrating the behavior of multiple components into a comprehensive network-based model, and by addressing questions that are not yet accessible to experimental analysis.

[1]  M. Kollef,et al.  The Epidemiology, Pathogenesis and Treatment of Pseudomonas aeruginosa Infections , 2012, Drugs.

[2]  E. Greenberg,et al.  A second N-acylhomoserine lactone signal produced by Pseudomonas aeruginosa. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D. Reeves Advantages and disadvantages of an in-vitro model with two compartments connected by a dialyser: results of experiments with ciprofloxacin. , 1985, The Journal of antimicrobial chemotherapy.

[4]  J. Gobburu,et al.  Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application. , 2002, International journal of clinical pharmacology and therapeutics.

[5]  J. Rello,et al.  Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. , 2010, The Journal of antimicrobial chemotherapy.

[6]  J. Roberts,et al.  A method for determining the free (unbound) concentration of ten beta-lactam antibiotics in human plasma using high performance liquid chromatography with ultraviolet detection. , 2012, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[7]  G. Drusano,et al.  Saturability of Granulocyte Kill of Pseudomonas aeruginosa in a Murine Model of Pneumonia , 2011, Antimicrobial Agents and Chemotherapy.

[8]  K. Bush,et al.  Affinity of Doripenem and Comparators to Penicillin-Binding Proteins in Escherichia coli and Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.

[9]  Roy Kishony,et al.  Drug interactions and the evolution of antibiotic resistance , 2009, Nature Reviews Microbiology.

[10]  O. Zak,et al.  Animal models as predictors of the safety and efficacy of antibiotics , 1990, European Journal of Clinical Microbiology and Infectious Diseases.

[11]  O. Cars,et al.  Pharmacodynamic effects of sub-MICs of benzylpenicillin against Streptococcus pyogenes in a newly developed in vitro kinetic model , 1996, Antimicrobial agents and chemotherapy.

[12]  S. Srivastava,et al.  Pharmacokinetic Mismatch Does Not Lead to Emergence of Isoniazid- or Rifampin-Resistant Mycobacterium tuberculosis but to Better Antimicrobial Effect: a New Paradigm for Antituberculosis Drug Scheduling , 2011, Antimicrobial Agents and Chemotherapy.

[13]  A. Lesse,et al.  Pharmacodynamics of Vancomycin at Simulated Epithelial Lining Fluid Concentrations against Methicillin-Resistant Staphylococcus aureus (MRSA): Implications for Dosing in MRSA Pneumonia , 2009, Antimicrobial Agents and Chemotherapy.

[14]  R. Hancock,et al.  Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa. , 2009, FEMS microbiology reviews.

[15]  M. Bergeron,et al.  Inoculum size effect on the MIC of cefoperazone, moxalactam, cefotaxime, cefoxitin and cephalothin for 118 strains of Haemophilus influenzae including 'tolerant' micro-organisms. , 1982, The Journal of antimicrobial chemotherapy.

[16]  William J Jusko,et al.  Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. , 2009, Drug metabolism and pharmacokinetics.

[17]  R. Hancock,et al.  Cationic antimicrobial peptides activate a two‐component regulatory system, PmrA‐PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa , 2003, Molecular microbiology.

[18]  J. Klastersky,et al.  An artificial capillary in vitro kinetic model of antibiotic bactericidal activity. , 1981, The Journal of infectious diseases.

[19]  J. Blaser In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives. , 1985, The Journal of antimicrobial chemotherapy.

[20]  Y. Yano,et al.  Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. , 1998, Journal of pharmaceutical sciences.

[21]  P. Seed,et al.  Regulation of las and rhl quorum sensing in Pseudomonas aeruginosa , 1997, Journal of bacteriology.

[22]  K. Bush The coming of age of antibiotics: discovery and therapeutic value , 2010, Annals of the New York Academy of Sciences.

[23]  Jianguo Zhi,et al.  Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due toPseudomonas aeruginosa , 1988, Journal of Pharmacokinetics and Biopharmaceutics.

[24]  W. Wehrli,et al.  Rifampin: mechanisms of action and resistance. , 1983, Reviews of infectious diseases.

[25]  C. Kloft,et al.  In vitro pharmacodynamic models to determine the effect of antibacterial drugs. , 2010, The Journal of antimicrobial chemotherapy.

[26]  K. Marotti,et al.  Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions , 1997, Antimicrobial agents and chemotherapy.

[27]  M. Zeitlinger,et al.  Penetration of Doripenem into Skeletal Muscle and Subcutaneous Adipose Tissue in Healthy Volunteers , 2011, Antimicrobial Agents and Chemotherapy.

[28]  J. Li,et al.  Heteroresistance to Colistin in Multidrug-Resistant Acinetobacter baumannii , 2006, Antimicrobial Agents and Chemotherapy.

[29]  H. Kitano Systems Biology: A Brief Overview , 2002, Science.

[30]  R. Hancock,et al.  Adaptive Resistance to the “Last Hope” Antibiotics Polymyxin B and Colistin in Pseudomonas aeruginosa Is Mediated by the Novel Two-Component Regulatory System ParR-ParS , 2010, Antimicrobial Agents and Chemotherapy.

[31]  Neang S. Ly,et al.  Development and Qualification of a Pharmacodynamic Model for the Pronounced Inoculum Effect of Ceftazidime against Pseudomonas aeruginosa , 2008, Antimicrobial Agents and Chemotherapy.

[32]  B. Iglewski,et al.  The chain of command in Pseudomonas quorum sensing. , 1997, Trends in microbiology.

[33]  O. Cars,et al.  Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. , 2005, The Journal of antimicrobial chemotherapy.

[34]  W. Konings,et al.  Mechanism of action of the peptide antibiotic nisin in liposomes and cytochrome c oxidase-containing proteoliposomes , 1991, Applied and environmental microbiology.

[35]  J. Buynak β-Lactamase inhibitors: a review of the patent literature (2010 – 2013) , 2013, Expert opinion on therapeutic patents.

[36]  D. Orr,et al.  Mode of action of ceftazidime: affinity for the penicillin-binding proteins of Escherichia coli K12, Pseudomonas aeruginosa and Staphylococcus aureus. , 1983, The Journal of antimicrobial chemotherapy.

[37]  Neang S. Ly,et al.  Quantifying Subpopulation Synergy for Antibiotic Combinations via Mechanism-Based Modeling and a Sequential Dosing Design , 2013, Antimicrobial Agents and Chemotherapy.

[38]  M. Nishida,et al.  New in vitro kinetic model for evaluating bactericidal efficacy of antibiotics , 1980, Antimicrobial Agents and Chemotherapy.

[39]  E. Schneider,et al.  Comparison of in vivo and in vitro SCE induction. , 1982, Mutation research.

[40]  S. Lory,et al.  Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen , 2000, Nature.

[41]  W R Greco,et al.  The search for cytotoxic synergy between anticancer agents: a case of Dorothy and the ruby slippers? , 1996, Journal of the National Cancer Institute.

[42]  C. Gomersall,et al.  The pharmacokinetics of once-daily dosing of ceftriaxone in critically ill patients. , 2001, The Journal of antimicrobial chemotherapy.

[43]  Réka Albert,et al.  Modeling Systems-Level Regulation of Host Immune Responses , 2007, PLoS Comput. Biol..

[44]  Ronald N. Jones,et al.  10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[45]  A. MacGowan,et al.  A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital. , 2001, The Journal of antimicrobial chemotherapy.

[46]  C. Janeway,et al.  A human homologue of the Drosophila Toll protein signals activation of adaptive immunity , 1997, Nature.

[47]  Neang S. Ly,et al.  Resurgence of Colistin: A Review of Resistance, Toxicity, Pharmacodynamics, and Dosing , 2010, Pharmacotherapy.

[48]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[49]  Brian T. Tsuji,et al.  Front-Loaded Linezolid Regimens Result in Increased Killing and Suppression of the Accessory Gene Regulator System of Staphylococcus aureus , 2012, Antimicrobial Agents and Chemotherapy.

[50]  C. Janion Inducible SOS Response System of DNA Repair and Mutagenesis in Escherichia coli , 2008, International journal of biological sciences.

[51]  C. Gyles,et al.  Pathogenesis of bacterial infections in animals , 2004 .

[52]  J. Bartlett,et al.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[53]  George L. Drusano,et al.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.

[54]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[55]  I. P. Fomina,et al.  A dynamic model for in-vitro evaluation of antimicrobial action by simulation of the pharmacokinetic profiles of antibiotics. , 1989, The Journal of antimicrobial chemotherapy.

[56]  G. Drusano,et al.  Use of Preclinical Data for Selection of a Phase II/III Dose for Evernimicin and Identification of a Preclinical MIC Breakpoint , 2001, Antimicrobial Agents and Chemotherapy.

[57]  Wojciech Krzyzanski,et al.  Assessment of Drug Interactions Relevant to Pharmacodynamic Indirect Response Models , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[58]  Neang S. Ly,et al.  New Dosing Strategies for an Old Antibiotic: Pharmacodynamics of Front-Loaded Regimens of Colistin at Simulated Pharmacokinetics in Patients with Kidney or Liver Disease , 2013, Antimicrobial Agents and Chemotherapy.

[59]  S. Akira,et al.  Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. , 2011, Immunity.

[60]  D. Paterson,et al.  Clinically Relevant Plasma Concentrations of Colistin in Combination with Imipenem Enhance Pharmacodynamic Activity against Multidrug-Resistant Pseudomonas aeruginosa at Multiple Inocula , 2011, Antimicrobial Agents and Chemotherapy.

[61]  R. H. Baltz Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. , 2009, Current opinion in chemical biology.

[62]  M. Bounthavong,et al.  Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination , 2013 .

[63]  G. Drusano,et al.  Impact of Burden on Granulocyte Clearance of Bacteria in a Mouse Thigh Infection Model , 2010, Antimicrobial Agents and Chemotherapy.

[64]  G. Drusano,et al.  The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill of Mycobacterium tuberculosis as Determined in a Hollow-Fiber Infection Model , 2010, mBio.

[65]  J. Blaser,et al.  Two compartment kinetic model with multiple artificial capillary units. , 1985, The Journal of antimicrobial chemotherapy.

[66]  V. Tamassia,et al.  New In Vitro Model to Study the Effect of Antibiotic Concentration and Rate of Elimination on Antibacterial Activity , 1978, Antimicrobial Agents and Chemotherapy.

[67]  R. Hancock,et al.  PhoP–PhoQ homologues in Pseudomonas aeruginosa regulate expression of the outer‐membrane protein OprH and polymyxin B resistance , 1999, Molecular microbiology.

[68]  A. Louie,et al.  Impact of Granulocytes on the Antimicrobial Effect of Tedizolid in a Mouse Thigh Infection Model , 2011, Antimicrobial Agents and Chemotherapy.

[69]  Robert Leary,et al.  Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. , 2003, The Journal of clinical investigation.

[70]  S. Keil,et al.  Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models , 1995, Antimicrobial agents and chemotherapy.

[71]  M. Laub,et al.  Specificity in two-component signal transduction pathways. , 2007, Annual review of genetics.

[72]  Alan Forrest,et al.  Novel Pharmacokinetic-Pharmacodynamic Model for Prediction of Outcomes with an Extended-Release Formulation of Ciprofloxacin , 2004, Antimicrobial Agents and Chemotherapy.

[73]  A. Vinks,et al.  Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion , 1997, Antimicrobial agents and chemotherapy.

[74]  Mats O. Karlsson,et al.  Semimechanistic Pharmacokinetic/Pharmacodynamic Model for Assessment of Activity of Antibacterial Agents from Time-Kill Curve Experiments , 2006, Antimicrobial Agents and Chemotherapy.

[75]  J. Roberts,et al.  Protein Binding of β-Lactam Antibiotics in Critically Ill Patients: Can We Successfully Predict Unbound Concentrations? , 2013, Antimicrobial Agents and Chemotherapy.

[76]  W. Craig,et al.  Animal model pharmacokinetics and pharmacodynamics: a critical review. , 2002, International journal of antimicrobial agents.

[77]  Neang S. Ly,et al.  Pharmacodynamic Variability beyond That Explained by MICs , 2013, Antimicrobial Agents and Chemotherapy.

[78]  Neang S. Ly,et al.  Attenuation of Colistin Bactericidal Activity by High Inoculum of Pseudomonas aeruginosa Characterized by a New Mechanism-Based Population Pharmacodynamic Model , 2010, Antimicrobial Agents and Chemotherapy.

[79]  F. Tangy,et al.  Mechanism of action of aminoglycoside antibiotics. Binding studies of tobramycin and its 6'-N-acetyl derivative to the bacterial ribosome and its subunits. , 1979, European journal of biochemistry.

[80]  Yaning Wang,et al.  Impact of Pharmacometric Analyses on New Drug Approval and Labelling Decisions , 2011, Clinical pharmacokinetics.

[81]  J. Prescott,et al.  Pathogenesis of Bacterial Infections in Animals: Gyles/Pathogenesis of Bacterial Infections in Animals , 2010 .

[82]  Manuel T. Silva,et al.  Neutrophils and macrophages work in concert as inducers and effectors of adaptive immunity against extracellular and intracellular microbial pathogens , 2010, Journal of leukocyte biology.

[83]  E. R. Garrett,et al.  Kinetics and mechanisms of action of drugs on microorganisms. XI. Effect of erythromycin and its supposed antagonism with lincomycin on the microbial growth of Escherichia coli. , 1970, Journal of pharmaceutical sciences.

[84]  J. Korth-Bradley,et al.  Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. , 2006, The Journal of antimicrobial chemotherapy.

[85]  D. Stevens,et al.  Penicillin-binding protein expression at different growth stages determines penicillin efficacy in vitro and in vivo: an explanation for the inoculum effect. , 1993, The Journal of infectious diseases.

[86]  P. McNamara,et al.  Pharmacodynamic Modeling of Ciprofloxacin Resistance in Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.

[87]  W. Hammes,et al.  On the Mechanism of Action of Vancomycin: Inhibition of Peptidoglycan Synthesis in Gaffkya homari , 1974, Antimicrobial Agents and Chemotherapy.

[88]  C Garnett,et al.  Impact of Pharmacometric Reviews on New Drug Approval and Labeling Decisions—a Survey of 31 New Drug Applications Submitted Between 2005 and 2006 , 2007, Clinical pharmacology and therapeutics.

[89]  M. Webber,et al.  Molecular mechanisms of antibiotic resistance , 2014, Nature Reviews Microbiology.

[90]  W. Greco,et al.  The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.

[91]  E. R. Garrett,et al.  Kinetics and mechanisms of action of drugs on microorganisms. VII. Quantitative adherence of sulfonamide action on microbial growth to a receptor-site model. , 1967, Journal of pharmaceutical sciences.

[92]  T. Cebula,et al.  Molecular analysis of mutS expression and mutation in natural isolates of pathogenic Escherichia coli. , 2003, Microbiology.

[93]  L. Pan,et al.  Plasmid-mediated quinolone resistance – current knowledge and future perspectives , 2013, The Journal of international medical research.

[94]  Neang S. Ly,et al.  Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies. , 2016, The Journal of antimicrobial chemotherapy.